Safety of certolizumab pegol in plaque psoriasis: pooled 96-week data from three phase 3, multicenter, randomized, placebo -controlled studies (CIMPASI-1, CIMPASI-z and CIMPACT)

被引：0

作者：

Blauvelt, A. ^{[1
]}

Strober, B. ^{[2
,3
]}

Langley, R. ^{[4
]}

Kavanagh, S. ^{[5
]}

Arendt, C. ^{[6
]}

Boehnlein, M. ^{[7
]}

Lebwohl, M. ^{[8
]}

Reich, K. ^{[9
,10
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Univ Connecticut, Ctr Hlth, Farmington, CT USA

[3] Prob Med Res, Waterloo, ON, Canada

[4] Dalhousie Univ, Halifax, NS, Canada

[5] UCB Pharma, Raleigh, NC USA

[6] UCB Pharma, Brussels, Belgium

[7] UCB Pharma, Monheim, Germany

[8] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[9] SCIderm Res Inst, Hamburg, Germany

[10] Dermatologikum Berlin, Berlin, Germany

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷

关键词：

Certolizumab Pegol; Psoriasis; Safety;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P032

引用

页码：21 / 22

页数：2

共 2 条

[1] Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) [J].

Gottlieb, Alice B. ;

Blauvelt, Andrew ;

Thaci, Diamant ;

Leonardi, Craig L. ;

Poulin, Yves ;

Drew, Janice ;

Peterson, Luke ;

Arendt, Catherine ;

Burge, Daniel ;

Reich, Kristian .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) :302-+

[2] Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-and placebo-controlled study (CIMPACT) [J].

Lebwohl, Mark ;

Blauvelt, Andrew ;

Paul, Carle ;

Sofen, Howard ;

Weglowska, Jolanta ;

Piguet, Vincent ;

Burge, Daniel ;

Rolleri, Robert ;

Drew, Janice ;

Peterson, Luke ;

Augustin, Matthias .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) :266-+

← 1 →